#AANAM – Biogen Offers Update on Development Plans for MS Therapies

#AANAM – Biogen Offers Update on Development Plans for MS Therapies

Publication date: May 15, 2019

This post was originally published on this site At the 2019 annual meeting of the American Academy of Neurology (AAN), Multiple Sclerosis News Today sat down with Bernd Kieseier, MD, global head of multiple sclerosis at Biogen, to discuss the company’s portfolio, latest data, and therapeutic development plans in the field of multiple sclerosis (MS). Kieseier said there is a need for a personalized approach to treat MS to find the exact therapy for each patient. -The highlight is clearly our commitment to identifying pathways toward a personalized medicine approach, optimizing the benefit-risk balance for our therapeutics, and taking the field forward by developing and offering new therapies,” Kieseier said. Neurofilament light as a disease biomarker This personalized medicine approach -has multiple flavors,” but Kieseier emphasized the possible use of a potential biomarker called neurofilament light chain (NfL), which is released from damaged neurons and, as such, can be a good marker of damage to the nervous system. -There’s good evidence that [NfL is] a marker you can use to dissect the trajectory of individual patients, like this is a patient that has a rather poor prognosis versus someone who is probably a little bit more stable,” Kieseier said, which might help in the process of decision-making in clinical practice, and allow clinicians to -say, ‘Well, this patient probably needs a different therapy. ‘ -The [anti-JCV antibody] index is a tool that defines the risk that you potentially might develop [PML],” Kieseier said, explaining that this can allow doctors and patients to accurately weigh the risks when considering what treatment is best. -I personally think that natalizumab (Tysabri) is one of the best therapies we have to offer to our patients, but the risk-benefit is a discussion the physician should have with the patient, and the antibody index is a tool to actually discuss the PML risk associated with natalizumab,” he said. Oral options: Tecfidera and Vumerity Kieseier also discussed data on two other Biogen MS therapies: Tecfidera (dimethyl fumarate) and Vumerity (diroximel fumarate; formerly BIIB098 or ALKS 8700). Kieseier said there is an -ongoing discussion” as further trials, such as a second Phase 2 trial of opicinumab and -other products that also address the component of repair,” are considered and planned for these and similar therapies, including BIIB061. Designing trials to truly assess repair is still -a work in progress,” Kieseier said, but added that he and colleagues are -super excited” at the prospect of MS therapies that would help the nervous system heal, not just prevent further damage. The post #AANAM – Biogen Offers Update on Development Plans for MS Therapies appeared first on Multiple Sclerosis News Today.

Concepts Keywords
Antibodies Human polyomavirus 2
Antibody Progressive multifocal leukoencephalopathy
Assay Opicinumab
Biogen Natalizumab
Biomarker Dimethyl fumarate
Biomarkers Spinal muscular atrophy
Blood Biogen
Brain Monoclonal antibodies
Cerebrospinal Fluid Medical specialties
Clinical Trial Viruses
Clinical Trials Immunology
Day Hospital Immunosuppressants
European Union Oral therapy
FDA Intravenous infusions
Fluid MS
Fumarate Magnetic resonance imaging
Gastrointestinal Magnetic resonance imaging
Immune Cell Antibodies
Infection MRI
Inflammation
Intravenous
John Cunningham
Magnetic Resonance Imaging
MRI
Multiple Sclerosis
Natalizumab
Nervous System
Neurofilament
Neurology
Neurons
NfL
NOVA
Personalized Medicine
Physician
PML
Prognosis
Progressive Multifocal Leukoencephalopathy
Relapse
Siemens
Spinal Cord
Street
Tolerability
Tysabri
Virus

Semantics

Type Source Name
disease MESH Development
gene UNIPROT SLC35G1
disease MESH Multiple Sclerosis
disease DOID Multiple Sclerosis
drug DRUGBANK Isoxaflutole
gene UNIPROT TNFSF14
disease MESH multiple
gene UNIPROT NEFL
gene UNIPROT MAGEE1
gene UNIPROT SIRPA
drug DRUGBANK Nonoxynol-9
disease MESH diagnosis
gene UNIPROT KIT
disease DOID PML
gene UNIPROT PML
drug DRUGBANK Natalizumab
disease MESH inflammation
disease MESH relapse
disease MESH progressive multifocal leukoencephalopathy
disease MESH infection
gene UNIPROT BEST1
drug DRUGBANK Dimethyl fumarate
disease DOID relapsing-remitting MS
gene UNIPROT SHOX2
gene UNIPROT MAP6
gene UNIPROT CYREN

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *